Drug archive
Bortezomib (Systemic)Proper Use
Archived drug information. This USP DI monograph is kept for reference and dates from the mid-2000s. Doses, warnings, interactions and brand names may have changed, and some products are no longer sold. Always follow your prescriber, your pharmacist and the current label, for example on DailyMed.
Proper Use of This Medicine
Dosing - The dose of bortezomib will be different for different patients. Follow your doctor's orders or the directions on the label . The following information includes only the average doses of bortezomib. If you have any questions about the proper dose of bortezomib, ask your doctor.
-
For injection
dosage form
-
For treatment of multiple myeloma
-
Adults -
- Patients without symptoms or with Grade 1 symptoms of peripheral neuropathy (paresthesias and/or loss of reflexes without pain or loss of function) - 1.3 milligrams (mg) per m2 twice weekly for two weeks (days 1, 4, 8, and 11) followed by a 10-day rest period (days 12-21). At least 72 hours should elapse between consecutive dose.
- Patients with Grade 1 with pain or Grade 2 symptoms of peripheral neuropathy (interfering with function but not with activities of daily living) - 1 milligram (mg) per m2 twice weekly for two weeks (days 1, 4, 8, and 11) followed by a 10-day rest period (days 12-21). At least 72 hours should elapse between consecutive dose.
- Patients with Grade 2 with pain or Grade 3 symptoms of peripheral neuropathy (interfering with activities of daily living) - Your doctor will withhold therapy until toxicity resolves. When toxicity resolves your doctor will reduce your dose to 0.7 mg/m2 once per week.
- Patients with Grade 4 symptoms of peripheral neuropathy (permanent sensory loss that interferes with function) - Your doctor will discontinue therapy
- Children - Bortezomib is not usually recommended in children.
-
Adults -
-
For treatment of multiple myeloma
Missed dose - Discuss with your doctor what to do